Bajaj Healthcare Ltd
Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations[1]
- Market Cap ₹ 1,995 Cr.
- Current Price ₹ 632
- High / Low ₹ 719 / 263
- Stock P/E 45.7
- Book Value ₹ 141
- Dividend Yield 0.15 %
- ROCE 8.23 %
- ROE -12.2 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
Cons
- Stock is trading at 4.49 times its book value
- The company has delivered a poor sales growth of 5.04% over past five years.
- Company has a low return on equity of 7.77% over last 3 years.
- Promoter holding has decreased over last 3 years: -8.07%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
171 | 205 | 218 | 223 | 231 | 327 | 370 | 410 | 657 | 680 | 646 | 473 | 522 | |
158 | 186 | 189 | 193 | 200 | 288 | 327 | 362 | 521 | 561 | 534 | 397 | 435 | |
Operating Profit | 13 | 19 | 29 | 30 | 31 | 39 | 43 | 48 | 136 | 119 | 112 | 76 | 87 |
OPM % | 7% | 9% | 13% | 14% | 13% | 12% | 12% | 12% | 21% | 17% | 17% | 16% | 17% |
0 | 0 | 0 | 0 | 2 | 2 | 1 | 7 | 7 | 1 | -19 | -105 | -33 | |
Interest | 6 | 7 | 8 | 8 | 8 | 8 | 8 | 7 | 8 | 13 | 18 | 30 | 28 |
Depreciation | 8 | 9 | 9 | 9 | 11 | 11 | 11 | 12 | 16 | 18 | 17 | 28 | 28 |
Profit before tax | -2 | 3 | 12 | 14 | 14 | 23 | 24 | 36 | 119 | 90 | 58 | -86 | -2 |
Tax % | -31% | 40% | 37% | 39% | 43% | 33% | 33% | 30% | 30% | 20% | 25% | -3% | |
-1 | 2 | 8 | 8 | 8 | 15 | 16 | 25 | 83 | 71 | 43 | -84 | -2 | |
EPS in Rs | -1.18 | 2.19 | 8.34 | 3.04 | 2.83 | 5.50 | 5.91 | 9.14 | 30.11 | 25.87 | 15.59 | -30.36 | -1.55 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 5% | 0% | 0% | 5% | 6% | 6% | -3% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 5% |
3 Years: | -10% |
TTM: | 6% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 51% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 43% |
3 Years: | 21% |
1 Year: | 101% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 14% |
3 Years: | 8% |
Last Year: | -12% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2 | 2 | 2 | 7 | 7 | 7 | 7 | 14 | 14 | 14 | 14 | 14 | 16 |
Reserves | 26 | 28 | 78 | 82 | 92 | 107 | 122 | 164 | 245 | 315 | 354 | 265 | 430 |
72 | 72 | 70 | 81 | 75 | 87 | 81 | 91 | 181 | 257 | 415 | 333 | 206 | |
31 | 43 | 38 | 39 | 45 | 68 | 57 | 74 | 86 | 136 | 115 | 154 | 152 | |
Total Liabilities | 131 | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 804 |
54 | 56 | 108 | 130 | 128 | 127 | 128 | 162 | 208 | 270 | 366 | 253 | 240 | |
CWIP | 5 | 3 | 1 | 1 | 0 | 2 | 1 | 5 | 57 | 52 | 22 | 7 | 10 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
72 | 87 | 79 | 78 | 91 | 140 | 137 | 170 | 260 | 399 | 510 | 506 | 554 | |
Total Assets | 131 | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 804 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
14 | 17 | 28 | 25 | 22 | 17 | 25 | 21 | 44 | 1 | -22 | 92 | |
-8 | -9 | -17 | -31 | -8 | -12 | -13 | -28 | -109 | -75 | -93 | -11 | |
-7 | -8 | -11 | 5 | -13 | 2 | -13 | 3 | 75 | 62 | 131 | -97 | |
Net Cash Flow | -0 | 1 | -0 | -0 | 0 | 7 | -0 | -4 | 10 | -12 | 16 | -16 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 95 | 98 | 86 | 70 | 83 | 90 | 77 | 88 | 55 | 99 | 110 | 139 |
Inventory Days | 43 | 51 | 50 | 56 | 45 | 57 | 45 | 54 | 94 | 143 | 199 | 206 |
Days Payable | 51 | 68 | 63 | 46 | 51 | 74 | 45 | 80 | 67 | 94 | 81 | 128 |
Cash Conversion Cycle | 87 | 81 | 73 | 80 | 78 | 73 | 77 | 62 | 82 | 148 | 228 | 217 |
Working Capital Days | 71 | 62 | 52 | 52 | 58 | 61 | 66 | 76 | 90 | 142 | 208 | 226 |
ROCE % | 5% | 10% | 16% | 13% | 13% | 16% | 16% | 18% | 36% | 20% | 14% | 8% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
4 Mar - Of schedule of Analyst/ Institutional Investor Meetings under the SEBI (LODR) Regulations, 2015
- Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011 25 Feb
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Feb - Newspaper Publication of the Financial Results for the Quarter & Nine months ended 31st December 2024
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
11 Feb - Bajaj Healthcare reports Q3 FY25 financial results.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
11 Feb - Monitoring Agency Report for Q4 2024 issued.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1][2][3]
BHL is focused on development, supply, manufacturing of Amino Acids, Nutritional Supplements and Active Pharma Ingredients for Pharmaceutical, Nutraceuticals and Food industries. It manufactures active pharmaceutical ingredients and formulations in the form of tablets, capsules, powder, etc. for ~550+ clients, exporting bulk drugs to ~62+ countries in Europe, USA, Africa, Australia, etc.